RESUMEN
BACKGROUND: Xylometazoline is a nasal decongestant spray that constricts nasal blood vessels and increases nasal airflow, enabling patients with a blocked nose to breathe more easily. The purpose of this study was to characterize objectively and subjectively the decongestant and additional effects of xylometazoline in the common cold. METHODS: A double-blind, placebo-controlled, parallel group study was performed. Patients with a common cold (n = 61) were treated with xylometazoline 0.1% (n = 29) or placebo (saline solution; n = 32; 1 spray three times a day for up to 10 days). The primary objective was to determine the decongestant effect (nasal conductance); the secondary objectives were to determine the peak subjective effect (visual analog scale), duration of relief of nasal congestion, total and individual cold symptoms and general well-being (patients' daily diary), and adverse events (AEs). RESULTS: The decongestant effect of xylometazoline was significantly greater than placebo, as shown by the nasal conductance at 1 hour (384.23 versus 226.42 cm(3)/s; p Asunto(s)
Resfriado Común/tratamiento farmacológico
, Imidazoles/administración & dosificación
, Descongestionantes Nasales/administración & dosificación
, Administración Intranasal
, Agonistas alfa-Adrenérgicos
, Adulto
, Relación Dosis-Respuesta a Droga
, Método Doble Ciego
, Femenino
, Estudios de Seguimiento
, Humanos
, Masculino
, Satisfacción del Paciente
, Estudios Retrospectivos
, Resultado del Tratamiento